Skip Navigation LinksHome > January 2014 - Volume 52 - Issue 1 > Establishment of an 11-Year Cohort of 8733 Pediatric Patient...
Text sizing:
A
A
A
Medical Care:
doi: 10.1097/MLR.0b013e31824deff9
Applied Methods

Establishment of an 11-Year Cohort of 8733 Pediatric Patients Hospitalized at United States Free-standing Children’s Hospitals With De Novo Acute Lymphoblastic Leukemia From Health Care Administrative Data

Fisher, Brian T. DO, MSCE*,†,‡,§; Harris, Tracey BSc; Torp, Kari BA; Seif, Alix E. MD, MPH‡,∥; Shah, Ami BS, BA; Huang, Yuan-Shung V. MS*,†; Bailey, L. Charles MD, PhD‡,∥; Kersun, Leslie S. MD, MSCE‡,∥; Reilly, Anne F. MD, MPH‡,∥; Rheingold, Susan R. MD‡,∥; Walker, Dana MD‡,∥; Li, Yimei PhD; Aplenc, Richard MD, PhD‡,§,∥,¶

Collapse Box

Abstract

Background:

Acute lymphoblastic leukemia (ALL) accounts for almost one quarter of pediatric cancer in the United States. Despite cooperative group therapeutic trials, there remains a paucity of large cohort data on which to conduct epidemiology and comparative effectiveness research studies.

Research Design:

We designed a 3-step process utilizing International Classification of Diseases-9 Clinical Modification (ICD-9) discharge diagnoses codes and chemotherapy exposure data contained in the Pediatric Health Information System administrative database to establish a cohort of children with de novo ALL. This process was validated by chart review at 1 of the pediatric centers.

Results:

An ALL cohort of 8733 patients was identified with a sensitivity of 88% [95% confidence interval (CI), 83%–92%] and a positive predictive value of 93% (95% CI, 89%–96%). The 30-day all cause inpatient case fatality rate using this 3-step process was 0.80% (95% CI, 0.63%–1.01%), which was significantly different than the case fatality rate of 1.40% (95% CI, 1.23%–1.60%) when ICD-9 codes alone were used.

Conclusions:

This is the first report of assembly and validation of a cohort of de novo ALL patients from a database representative of free-standing children’s hospitals across the United States. Our data demonstrate that the use of ICD-9 codes alone to establish cohorts will lead to substantial patient misclassification and result in biased outcome estimates. Systematic methods beyond the use of just ICD-9 codes must be used before analysis to establish accurate cohorts of patients with malignancy. A similar approach should be followed when establishing future cohorts from administrative data.

Copyright © 2012 by Lippincott Williams & Wilkins

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.